Modulight as an investment
Modulight Corporation is a Finnish technology company that designs, markets and produces laser products including semiconductors, laser modules and complete cloud-connected laser platforms, as well as related software and services for demanding pharmaceutical and technology companies and target markets around the world.
In January 2023, Modulight Corporation received market authorization from the U.S. Food and Drug Administration (FDA) for its ML6710i laser device for the treatment of wet age-related macular degeneration (AMD) in the United States.
In 2022, Modulight’s was EUR 4.6 million. The company’s EBITDA in 2022 was EUR -5.9 million and the EBITDA margin was -129.1 percent.
Modulight's customers use the company's comprehensive laser product solutions in the pharmaceutical and biomedical treatments and products they offer, where laser technology brings significant added value. Modulight’s customers include in total more than ten international pharmaceutical companies and Fortune 500 listed companies as well as several well-known cancer research institutes and universities in the United States, Japan and Europe.
Modulight has over 20 years of experience in medical applications, the development and manufacture of lasers and optics. Since 2014, the company’s main focus has been on providing laser solutions for the medicine and biomedicine sectors. More specifically, the company has been involved in developing various laser-based treatment methods for indications within oncology and ophthalmology. Modulight believes that its expertise will bring the company a competitive market position.
Expert in lasers and optics
years of experience in medical applications, the development and manufacture of lasers and optics
in total more than ten international pharmaceutical companies and Fortune 500 listed companies as customers
projects ongoing at the end of 2022, share of large multinational companies grew